Structure Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GPCR research report →
Range $70 – $111
Price Chart
About the company
Structure Therapeutics Inc. , an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R).
- CEO
- Raymond C. Stevens
- IPO
- 2023
- Employees
- 220
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on GPCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $928.55M
- P/E
- -4.45
- PEG
- 0.17
- P/S
- 0.00
- P/B
- 1.04
- EV/EBITDA
- -2.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.24%
- ROIC
- -27.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-3,899,285+0.0%
- Op Income
- $-287,567,533
- Net Income
- $-141,202,000-15.2%
- EPS
- $-2.40-2.6%
- OCF Growth
- -90.5%
- FCF Growth
- -91.5%
- 52W High
- $94.90
- 52W Low
- $16.06
- 50D MA
- $25.94
- 200D MA
- $44.24
- Beta
- -1.52
- RSI (14)
- 25
- Avg Volume
- 1.17M
No earnings-call transcripts are available for GPCR yet.
- Free Float
- 95.1%
- Shares Outstanding
- 57.57M
- Float Shares
- 54.73M
of shares held by institutions
203 13F filers
Buy/sell ratio 0.48. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GPCR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Thomas Richard CarperSenate · DE | Sell | Oct 4, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Wellington Management Group Llp | 9.76M | ▲ 2.38M |
| Fmr LLC | 9.35M | ▲ 1.54M |
| Avoro Capital Advisors LLC | 6.56M | 0 |
| Jupiter Topco LLC | 5.20M | ▲ 5.20M |
| Janus Henderson Group Ltd. | 5.07M | ▲ 5.07M |
| Deep Track Capital, LP | 5.00M | ▲ 259.93K |
| Morgan Stanley | 2.82M | ▲ 10.14K |
| Bvf Inc/Il | 2.69M | ▼ 675.40K |
| Rtw Investments, LP | 2.28M | ▲ 674.63K |
| Baker Bros. Advisors LP | 1.43M | 0 |
| Orbimed Advisors LLC | 1.33M | ▼ 878.40K |
| Paradigm Biocapital Advisors LP | 1.30M | ▲ 1.30M |
Held by 109 ETFs
Biggest fund positions in GPCR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 26 | Coll Crespo Blas | other | 10,626 |
| Sep 21, 26 | Coll Crespo Blas | other | 12,024 |
| Sep 21, 26 | Coll Crespo Blas | other | 4,008 |
| Sep 21, 26 | Coll Crespo Blas | sell | 4,008 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 17,817 |
| Sep 1, 26 | Lin Xichen | other | 5,939 |
| Sep 1, 26 | Lin Xichen | sell | 1,300 |
| Sep 1, 26 | Lin Xichen | sell | 4,539 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GPCR coverage
Recent articles, reports, and earnings notes.

Should You Buy Corxel US Before the SPAC Merger Closes?
Corxel US is a clinical-stage biopharmaceutical company developing oral obesity and cardiometabolic therapies, and it is going public through a merger with Amanat Acquisition Corp. (Nasdaq: AMAN). The deal is expected to close in the first half of 2027, but shareholders should watch the cash raise and redemption math closely because dilution and trust leakage could reshape the setup.

Should You Buy the Palatin Technologies IPO? Here's the Setup
Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.
Want a deeper read on GPCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
zacks.com · Nov 13
Structure Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
globenewswire.com · Nov 9
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
zacks.com · Nov 9
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com · Nov 4
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91 According to Brokerages
defenseworld.net · Oct 21
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
globenewswire.com · Oct 19
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s Why
defenseworld.net · Oct 16
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
zacks.com · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.